BIOD-123

Biodel: Creating A Better, Faster Acting Insulin, The Next Big Thing For Diabetic Therapy
Biodel: Creating A Better, Faster Acting Insulin, The Next Big Thing For Diabetic Therapy
Seeking Alpha
Biodel
insulin
diabetes
BIOD-123
Flag link:
Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)
Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)
Yahoo
Biodel
BIOD-123
clinical trials
diabetes
type 1 diabetes
Flag link:
Is This a MannKind Killer?
Is This a MannKind Killer?
Motley Fool
MannKind
diabetes
Afrezza
BIOD-123
insulin
Biodel
Flag link:
Why Biodel Will Have Positive Phase II Results
Why Biodel Will Have Positive Phase II Results
Seeking Alpha
Biodel
BIOD-123
type 1 diabetes
type 2 diabetes
diabetes
Flag link:
3 Biotech Catalysts Primed To Be Successful In Q3
3 Biotech Catalysts Primed To Be Successful In Q3
Seeking Alpha
BIOD-123
Biodel
MannKind
Afrezza
GTx
Flag link:
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
Biotech Stock Mailbag: 2013 Clinical Trials Calendar
TheStreet.com
Zerenex
Xoma
Vical
Takeda
sovaprevir
Soluble Ferric Pyrophosphate
Rockwell Medical
Orexigen
MM-398
Merrimack Pharmaceuticals
MannKind
Keryx
GTx
GSK
gevokizumab
enobosarm
Coronado Biosciences
Contrave
CNDO-201
clinical trials
ChemoCentryx
CCX140
Biodel
BIOD-123
Amigal
Amicus Therapeutics
Alnylam
ALN-TTR02
Allovectin
Afrezza
Achillion
ACH-3102
Flag link:
The Run-Up Trade: Biodel's Insulin Trial Results
The Run-Up Trade: Biodel's Insulin Trial Results
TheStreet.com
insulin
diabetes
Biodel
BIOD-123
MannKind
Afrezza
Flag link:
Biodel: Reemerging From Obscurity In 2013
Biodel: Reemerging From Obscurity In 2013
Seeking Alpha
Biodel
Eli Lilly
BIOD-123
recombinant human insulin
BIOD-250
Flag link: